Research ArticleOpen AccessGoogle Scholar indexed
Benefit of Targeted Therapies in Metastatic Colon Cancer in the Ivorian Context
Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
- 1 Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
- 2 Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
- 3 Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
- 4 Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
- 5 Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
- 6 Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
- 7 Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
- 8 Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
- 9 Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire
Journal of Cancer Therapy·Volume 08 (2017)·Pages 785–792·Published 27 July 2017·DOI10.4236/jct.2017.88068
Copy link · social · email
Abstract
In our daily practice, the use of targeted therapies (Bevacizumab and rarely Cetuximab) in metastatic colic cancers is recent. Very few patients benefit from these therapies because of their high cost. In a cohort of 68 patients who received these therapies, a retrospective and prospective study was conducted over three years period (1 January 2013 to 31 December 2015) to evaluate their benefit in terms of quality of life, tolerance and overall survival. These targeted therapies provided a significant clinical and biological gain with acceptable toxicities (most often resolving spontaneously). Moreover, they have allowed a significant improvement in overall survival in first line metastatic treatment. The limiting factor remains their extremely high cost and therefore inaccessibility to the majority of our patients.
KeywordsCancer-Colon-Metastasis-Targeted Therapy
- Vilar, E., et al. (2010) Les 2 principales voies de carcinogenèse colorectale: Voie CIN (ou LOH); voie MSI. Nature Reviews Clinical Oncology, 7, 153-162. https://doi.org/10.1038/nrclinonc.2009.237
- Laurent-Puig, P., Agostini, J., Maley, K., et al. (2010) Oncogenèse colorectale. Bulletin du Cancer, 97, 1311-1321.
- Patel, G.S. and Karapetis, C.S. (2013) Personalized Treatment for Advanced Colorectal Cancer: KRAS and Beyond. Cancer Management and Research, 5, 387-400.
- Douillard, J.Y., Oliner, K.S., Siena, S., et al. (2013) Panitumumab-Folfox4 Treatment and RAS Mutations in Colorectal Cancer. The New England Journal of Medicine, 369, 1023-1034. https://doi.org/10.1056/NEJMoa1305275
- Edwin, R.F., Richard, S., Alka, P., et al. (1989) Dukes’ Classification Revisited. Findings from the National Surgical Adjuvant Breast and Bowel Projects (Protocol r-01). Cancer, 64, 2354-2360. https://doi.org/10.1002/1097-0142(19891201)64:11 3.0.CO;2-#
- Duffaud, F. and Therasse, P. (2000) Nouvelles Recommandations Pour l’évaluation de la réponse tumorale dans les tumeurs solides. Bulletin du Cancer, 87, 881-886.
- Kaplan, E.L. and Meier, P. (1958) Non Parametric Estimation from Incomplete Observations. Journal of the American Statistical Association, 53, 457-481. https://doi.org/10.1080/01621459.1958.10501452
- Meyerhardt, J.A. and Mayer, R.J. (2005) Systemic Therapy for Colorectal Cancer. The New England Journal of Medicine, 352, 476-487. https://doi.org/10.1056/NEJMra040958
- Tol, J., Koopman, M., Cats, A., et al. (2009) Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. The New England Journal of Medicine, 360, 563-572. https://doi.org/10.1056/NEJMoa0808268
- De Roock, W., Claes, B., Bernasconi, D., et al. (2010) Effects of KRAS, BRAF, NRAS, and PI3KA Mutations on the Efficacy of Cetuximab plus Chemotherapy in Chemotherapy-Refractory Metastatic Colorectal Cancer: A Retrospective Consortium Analysis. The Lancet Oncology, 11, 753-762.
- Lenz, H.J., Van Cutsem, E., Khambata-Ford, S., et al. (2006) Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. Journal of Clinical Oncology, 24, 4914-4921. https://doi.org/10.1200/JCO.2006.06.7595
- Hecht, J.R., Patnaik, A., Berlin, J., et al. (2007) Panitumumab Monotherapy in Patients with Previously Treated Metastatic Colorectal Cancer. Cancer, 110, 980-988. https://doi.org/10.1002/cncr.22915